BTIG Reiterates Rating on ZVRA $ZVRA
Key Points
- BTIG now rates Zevra Therapeutics, Inc. ($ZVRA) "buy" with a $27.00 target.
- The Street's average $ZVRA price target is $27.89 (Strong Buy).
- $ZVRA last traded around $12.96.
BTIG reiterated its rating on Zevra Therapeutics, Inc. ($ZVRA) to a "buy" rating, with a price target of $27.00 in a recent research note.
Zevra Therapeutics, Inc. ($ZVRA) Stock
Zevra Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.